Adaptive Biotechnologies reports 55% revenue growth in 2025
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 12, 2026 7:30 AM ESTFull year MRD revenue growth of 46% driven by clonoSEQ® testing volume
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.
Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in... More